Related Experiment Videos
The BCR-ABL story: bench to bedside and back
1Molecular Biology Interdepartmental PhD Program/UCLA, Los Angeles, California 90095-1662, USA. sw@ucla.edu
Annual Review of Immunology
|March 23, 2004
Summary
Molecular targeted therapy, like imatinib mesylate for chronic myelogenous leukemia (CML), shows promise. However, cancer mutations can lead to drug resistance, highlighting the need for alternative treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The 21st century marks a paradigm shift in cancer therapy towards molecularly targeted treatments.
- Research integrating cytogenetics, retroviral oncology, protein phosphorylation, and chemical inhibitors has enabled targeted drug development.
Observation:
- Imatinib mesylate is a tyrosine kinase inhibitor targeting ABL, ARG, KIT, and PDGFR.
- This drug significantly impacts the treatment of chronic myelogenous leukemia (CML) and other cancers driven by specific tyrosine kinase activations.
Findings:
- Drug resistance in CML patients treated with imatinib is linked to structural mutations in ABL.
- Crystallographic studies reveal how these mutations enable cancer cells to evade imatinib's inhibitory effects.
Implications:
- The success and limitations of imatinib offer valuable insights for developing novel molecular targeted therapies.
- Understanding resistance mechanisms is crucial for advancing precision oncology and overcoming therapeutic challenges.